---
title: "Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49"
url: "https://aibio.space/news/molecular-partners-prices-20-million-offering-3-642-988-adss-5-49/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-10-28"
section: "Financings"
tickers: "SIX:MOLN"
source: "https://www.sec.gov/Archives/edgar/data/1745114/000162828024043937/exhibit991-6xk.htm"
summary: "The Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners."
---

By the aibio.space news desk.

Sources

- [Molecular Partners AG 6-K (2024-10-28)](https://www.sec.gov/Archives/edgar/data/1745114/000162828024043937/exhibit991-6xk.htm)

[MOLN](https://aibio.space/companies/molecular-partners/)

2024-10-28

# Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49

Tickers [MOLN](https://aibio.space/companies/molecular-partners/)

The Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners.

## Key facts

- **Company**: Molecular Partners AG (SIX: MOLN)

- **News type**: Financings

- **Primary source**: [Molecular Partners AG 6-K (2024-10-28)](https://www.sec.gov/Archives/edgar/data/1745114/000162828024043937/exhibit991-6xk.htm)

*Two people shaking hands across a table. Photo: Kristin Hardwick, CC0, via StockSnap. The picture shows the field, not the companies named.*

Molecular Partners AG announced on October 25, 2024 the pricing of an underwritten offering in the United States of 3,642,988 American Depositary Shares (ADSs) at an offering price of $5.49 per ADS. Each ADS represents one ordinary share. Total gross proceeds are approximately $20.0 million. Molecular Partners is selling all of the ADSs.

The offering included participation from a new investor, HBM Healthcare Investments Ltd, and multiple existing investors. Leerink Partners and TD Cowen are acting as joint bookrunning managers, LifeSci Capital is lead manager, and Zürcher Kantonalbank serves as settlement agent. The offering was expected to close on October 29, 2024, subject to customary closing conditions.

The company intends to use the net proceeds, together with existing cash and cash equivalents, to develop and expand its radiopharmaceutical pipeline and platform (Radio-DARPin Therapeutics) and for working capital and other general corporate purposes.

The securities are offered under an effective Form F-3 shelf registration statement filed with the SEC. The SIX Swiss Exchange pre-approved, subject to customary conditions, the listing of the new ordinary shares underlying the ADSs. The company's shares trade on both SIX and Nasdaq under the symbol "MOLN." The announcement was made as an ad hoc announcement under Art. 53 of the SIX listing rules.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

MOLN

Molecular Partners AG

SIX · Switzerland

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/molecular-partners-prices-20-million-offering-3-642-988-adss-5-49/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Molecular Partners prices $20 million offering of 3,642,988 ADSs at $5.49", 2024-10-28, https://aibio.space/news/molecular-partners-prices-20-million-offering-3-642-988-adss-5-49/